Adjuvant Abemaciclib Plus Endocrine Therapy for HR+, HER2-, High-risk Early Breast cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-year Efficacy Outcomes

被引：0

作者：

Andre, V. ^{[1
]}

Harbeck, N. ^{[2
]}

Rastogi, P. ^{[3
,4
]}

O'Shaughnessy, J. ^{[5
]}

Boyle, F. ^{[6
]}

Cortes, J.

Rugo, H. S. ^{[7
,8
]}

Goetz, M. P. ^{[9
]}

Hamilton, E. ^{[10
]}

Huang, C. -s.

Senkus, E. ^{[11
]}

Tryakin, A. ^{[12
]}

Neven, P. ^{[13
]}

Huober, J. ^{[14
]}

Wei, R. ^{[1
]}

Munoz, M. ^{[1
]}

Antonio, B. S. ^{[1
]}

Shahir, A. ^{[1
]}

Martin, M. ^{[15
]}

Johnston, S. ^{[16
]}

机构：

[1] Eli Lilly & Co, Indianapolis, IN USA

[2] LMU Univ Hosp, Breast Ctr, Comprehens Canc Ctr Munchen, Dept Gynecol & Obstet, Munich, Germany

[3] UPMC Hillman Canc Ctr, Pittsburgh, PA USA

[4] NSABP Fdn, Pittsburgh, PA USA

[5] Baylor Univ, Texas Oncol, US Oncol, Med Ctr, Dallas, TX USA

[6] Univ Sydney, Sydney Med Sch, Sydney, NSW, Australia

[7] Int Breast Canc Ctr IBCC, Quironsalud Grp, Barcelona, Spain

[8] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, Dept Med, San Francisco, CA USA

[9] Mayo Clin, Rochester, MN USA

[10] Sarah Cannon Res Inst Tennessee Oncol, Nashville, TN USA

[11] Med Univ Gdansk, Gdansk, Poland

[12] NN Blokhin Russian Canc Res Ctr, Moscow, Russia

[13] Univ Hosp Leuven, Multidisciplinary Breast Ctr, Louvain, Belgium

[14] Kantonsspital St Gallen, Breast Ctr, St Gallen, Switzerland

[15] Univ Complutense, Hosp Gen Univ Gregorio Maranon, CIBERONC, GEICAM, Madrid, Spain

[16] Royal Marsden NHS Fdn Trust, London, England

来源：

BREAST | 2025年 / 80卷

关键词：

D O I：

10.1016/j.breast.2025.103903

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P009

引用

页数：2

共 50 条

[21] Patient-reported outcomes (PROs) of Chinese patients (pts) in monarchE: Abemaciclib plus endocrine therapy (ET) in adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer (EBC) [J].

Zhang, Q. ;

Shen, K. ;

Song, C. ;

Ouyang, Q. ;

Liu, Z. ;

Liu, Q. ;

Wang, X. ;

Yang, Y. ;

Qian, C. ;

Shao, Z. .

ANNALS OF ONCOLOGY, 2022, 33 :S1432-S1432

[22] Cost-effectiveness analysis of abemaciclib and endocrine therapy combination for the adjuvant treatment of HR+/HER2-, node-positive, high-risk, early breast cancer [J].

Talwar, Ashna ;

Deshmukh, Ashish ;

Trivedi, Meghana ;

Aparasu, Rajender R. .

CANCER RESEARCH, 2023, 83 (07)

[23] Abemaciclib combined with endocrine therapy as adjuvant treatment for hormone-receptor-positive, HER2-, high-risk early breast cancer: 5-year Chinese population analysis of the phase III randomized monarchE study [J].

Zhang, Qingyuan ;

Shen, Kunwei ;

Song, Chuan-gui ;

Ouyang, Quchang ;

Liu, Zhenzhen ;

Liu, Qiang ;

Feng, Jifeng ;

Chiu, Joanne W. Y. ;

Tang, Jinhai ;

Jiang, Zefei ;

Tseng, Ling-Ming ;

Wang, Xiaojia ;

Yang, Liu ;

Qian, Chenxi ;

Shao, Zhimin .

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2024, 16

[24] Results from a pilot study exploring ctDNA detection using a tumor-informed assay in the monarchE trial of adjuvant abemaciclib with endocrine therapy in HR+, HER2-, node-positive, high-risk early breast cancer [J].

Loi, Sherene ;

Johnston, Stephen ;

Arteaga, Carlos ;

Graff, Stephanie ;

Chandarlapaty, Sarat ;

Goetz, Matthew ;

Desmedt, Christine ;

Reis-Filho, Jorge ;

Sasano, Hironobu ;

Rodrik-Outmezguine, Vanessa ;

Sireci, Anthony ;

Rubenstein, Cynthia Sandoval ;

Won, Helen ;

Liu, Deli ;

Litchfield, Lacey M. ;

Turner, Nicholas .

CANCER RESEARCH, 2024, 84 (09)

[25] Cost-effectiveness of abemaciclib plus endocrine therapy in high-risk HR+/HER2–early breast cancer in China [J].

Qiran Wei ;

YuTing Xu ;

Wei Liu ;

Xin Guan .

Cost Effectiveness and Resource Allocation, 21

[26] Cost-effectiveness of abemaciclib plus endocrine therapy in high-risk HR+/HER2-early breast cancer in China [J].

Wei, Qiran ;

Xu, Yuting ;

Liu, Wei ;

Guan, Xin .

COST EFFECTIVENESS AND RESOURCE ALLOCATION, 2023, 21 (01)

[27] Safety outcomes from monarchE: Phase 3 study of abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER-2-, node-positive, high risk, early breast cancer [J].

Rugo, H. ;

O'Shaughnessy, J. ;

Song, C. ;

Broom, R. ;

Gumus, M. ;

Yamashita, T. ;

San Antonio, B. ;

Shahir, A. ;

Zimmermann, A. ;

Zagouri, F. ;

Reinisch, M. .

BREAST, 2021, 56 :S23-S24

[28] Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study [J].

Fleming, G. F. ;

Pagani, O. ;

Regan, M. M. ;

Walley, B. A. ;

Francis, P. A. .

ANNALS OF ONCOLOGY, 2022, 33 (06) :658-658

[29] Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study [J].

Harbeck, N. ;

Rastogi, P. ;

Martin, M. ;

Tolaney, S. M. ;

Shao, Z. M. ;

Fasching, P. A. ;

Huang, C. S. ;

Jaliffe, G. G. ;

Tryakin, A. ;

Goetz, M. P. ;

Rugo, H. S. ;

Senkus, E. ;

Testa, L. ;

Andersson, M. ;

Tamura, K. ;

Del Mastro, L. ;

Steger, G. G. ;

Kreipe, H. ;

Hegg, R. ;

Sohn, J. ;

Guarneri, V ;

Cortes, J. ;

Hamilton, E. ;

Andre, V ;

Wei, R. ;

Barriga, S. ;

Sherwood, S. ;

Forrester, T. ;

Munoz, M. ;

Shahir, A. ;

San Antonio, B. ;

Nabinger, S. C. ;

Toi, M. ;

Johnston, S. R. D. ;

O'Shaughnessy, J. .

ANNALS OF ONCOLOGY, 2021, 32 (12) :1571-1581

[30] Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: safety and patient-reported outcomes from the monarchE study [J].

Rugo, H. S. ;

O'Shaughnessy, J. ;

Boyle, F. ;

Toi, M. ;

Broom, R. ;

Blancas, I ;

Gumus, M. ;

Yamashita, T. ;

Im, Y-H ;

Rastogi, P. ;

Zagouri, F. ;

Song, C. ;

Campone, M. ;

San Antonio, B. ;

Shahir, A. ;

Hulstijn, M. ;

Brown, J. ;

Zimmermann, A. ;

Wei, R. ;

Johnston, S. R. D. ;

Reinisch, M. ;

Tolaney, S. M. .

ANNALS OF ONCOLOGY, 2022, 33 (06) :616-627

← 1 2 3 4 5 →